Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

Jeffrey Cummings, Stuart Isaacson, Roger Mills, Hilde Williams, Kathy Chi-Burris, Anne Corbett, Rohit Dhall, Clive Ballard

Open source

DOI
10.1016/s0140-6736(13)62106-6
Published
2014-02
Container
The Lancet
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-13-62106-6,
  title = {Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial},
  author = {Jeffrey Cummings and Stuart Isaacson and Roger Mills and Hilde Williams and Kathy Chi-Burris and Anne Corbett and Rohit Dhall and Clive Ballard},
  year = {2014},
  journal = {The Lancet},
  doi = {10.1016/s0140-6736(13)62106-6},
  url = {https://doi.org/10.1016/s0140-6736(13)62106-6}
}

RIS

TY  - JOUR
TI  - Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
AU  - Jeffrey Cummings
AU  - Stuart Isaacson
AU  - Roger Mills
AU  - Hilde Williams
AU  - Kathy Chi-Burris
AU  - Anne Corbett
AU  - Rohit Dhall
AU  - Clive Ballard
PY  - 2014
JO  - The Lancet
DO  - 10.1016/s0140-6736(13)62106-6
UR  - https://doi.org/10.1016/s0140-6736(13)62106-6
ER  - 

APA

Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., & Ballard, C. (2014). Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(13)62106-6

Source records